Article PDF
Avoid common mistakes on your manuscript.
References
World Health Organization. Global Tuberculosis Report 2017. Geneva: WHO; 2017.
Hanson C, Osberg M, Brown J, Durham G, Chin DP. Finding the missing patients with tuberculosis: lessons learned from patient-pathway analyses in 5 countries. J Infect Dis 2017; 216;S686–S95.
Wells WA, Uplekar M, Pai M. Achieving systemic and scalable private sector engagement in tuberculosis care and prevention in asia. PLoS Med 2015;12;e1001842.
Sreeramareddy CT, Kishore P V, Menten J, Van den Ende J. Time delays in diagnosis of pulmonary tuberculosis: a systematic review of literature. BMC Infect Dis 2009;9;91.
Mistry N, Lobo E, Shah S, Rangan S, Dholakia Y. Pulmonary tuberculosis in Patna, India: durations, delays, and health care seeking behaviour among patients identified through household surveys. J Epidemiol Glob Health 2017;7;241–8.
Mistry N, Rangan S, Dholakia Y, Lobo E, Shah S, Patil A. Durations and delays in care seeking, diagnosis and treatment initiation in uncomplicated pulmonary tuberculosis patients in Mumbai, India. PLoS ONE 2016;11;e0152287.
Cazabon D, Alsdurf H, Satyanarayana S, et al. Quality of tuberculosis care in high burden countries: the urgent need to address gaps in the care cascade. Int J Infect Dis 2016.
Pai M, Furin J. Tuberculosis innovations mean little if they cannot save lives. Elife 2017;6;e25956.
World Health Organization. Policy update: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system for the diagnosis of pulmonary and extrapul-monary TB in adults and children 2013. http://www.stoptb.org/wg/gli/assets/documents/WHO%20Policy%20Statement%20on%20Xpert%20MTB-RIF%202013%20pre%20publication%2022102013.pdf (accessed).
Puri L, Oghor C, Denkinger CM, Pai M. Xpert MTB/RIF for tuberculosis testing: access and price in highly privatised health markets. Lancet Global Health 2016;4;e94–e5.
Clinton Health Access Initiative. Case study. Catalyzing the market for accurate tuberculosis testing in India’s extensive private sector through IPAQT. https://clintonhealthaccess.org/content/uploads/2016/06/Case-Study-India-IPAQT-June-2016.pdf 2016. (accessed 10.04.18.).
Raizada N, Khaparde SD, Salhotra VS, et al. Accelerating access to quality TB care for pediatric TB cases through better diagnostic strategy in four major cities of India. PLoS ONE 2018;13;e0193194.
Salje H, Andrews JR, Deo S, et al. The importance of implementation strategy in scaling up Xpert MTB/RIF for diagnosis of tuberculosis in the indian health-care system: a transmission model. PLoS Med 2014;11;e1001674.
Mascarenhas A. Diagnostic lab group in India to offer HCV and HIV tests at almost half the price. 2018. http://indianexpress.com/article/india/diagnostic-lab-group-in-india-to-offer-hcv-and-hiv-tests-at-almost-half-the-price-5090239/. Indian Express.
Ndlovu Z, Fajardo E, Mbofana E, et al. Multidisease testing for HIV and TB using the GeneXpert platform: a feasibility study in rural Zimbabwe. PLoS ONE 2018;13;e0193577.
Nash M, Ramapuram J, Kaiya R, Huddart S, Pai M, Baliga S. Use of the GeneXpert tuberculosis system for HIV viral load testing in India. Lancet Global Health 2017;5;e754–e5.
World Health Organization. WHO to develop Essential Diagnostics List. 2017. http://www.who.int/medicines/news/2017/WHO_develop_essential_diagnostics_list/en/; (accessed 21.04.18.).
Author information
Authors and Affiliations
Rights and permissions
This is an open access article under the CC BY-NC license (http://creativecommons.org/licences/by-nc/4.0/).
About this article
Cite this article
Ponnudurai, N., Denkinger, C.M., Van Gemert, W. et al. New TB Tools Need to be Affordable in the Private Sector: The Case Study of Xpert MTB/RIF. J Epidemiol Glob Health 8, 103–105 (2018). https://doi.org/10.2991/j.jegh.2018.04.005
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2991/j.jegh.2018.04.005